Background The ability to exercise is an important clinical outcome in COPD, and the
improvement in exercise capacity is recognized to be an important goal in the management …

Background We carried out a systematic review and meta-analysis with the aim to evaluate
the efficacy of long-acting bronchodilators on exercise capacity in COPD patients. Methods …

Background Persistent airflow limitation and dyspnoea may reduce chronic obstructive
pulmonary disease (COPD) patients exercise capacity and physical activity, undermining …

Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

Background The wide availability of long-acting muscarinic antagonist (LAMA)/long-acting
β2-agonist (LABA) fixed-dose combinations (FDCs) in the absence of head-to-head …

BACKGROUND: Data comparing two bronchodilators vs. one bronchodilator plus inhaled
corticosteroid (ICS) on hyperinflation and exercise endurance in chronic obstructive …

The most recent guidelines define COPD in a multidimensional way, nevertheless the
diagnosis is still linked to the limitation of airflow, usually measured by the reduction in the …

Objectives The aim of this study was to assess the current evidence for long-acting β2-
agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) …

Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …

Because there is a solid pharmacological rationale based on positive interactions between
long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) …